News
Dr. Marty Makary, FDA commissioner, joins 'Squawk Box' to discuss what hindsight tells science about the best route to take ...
Dr. Marty Makary, FDA commissioner, joins 'Squawk Box' to discuss what hindsight tells science about the best route to take ...
After 100 days as FDA Commissioner, Dr. Marty Makary lays out his vision for reform, starting with the broken systems he's ...
It is unclear how the Trump administration will consider affordability when reviewing a drug, as prices are usually ...
13h
Stocktwits on MSNFDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: ReportThe U.S. Food and Drug Administration may reportedly fast-track new drugs from pharmaceutical companies that “equalize” the ...
Makary, a surgical oncologist tapped by President Trump to serve as the the 27th FDA chief, joined NewsNation on Thursday to ...
Explore more
Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other ...
FDA Commissioner Marty Makary said during an interview with Bloomberg Television that his agency may expedite reviews of ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...
Opinion
10hon MSNOpinion
The Food and Drug Administration (FDA) can maintain its high bar for safety and efficacy, and also cut the waste and unnecessary delays in the regulatory process.
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results